胸苷磷酸化酶表达和受益于卡培他滨在晚期乳腺癌患者。

文章的细节

引用

复制到剪贴板

Andreetta C, Puppin C, Minisini化合价的F, Pegolo E, Damante G,住迪洛雷托C, Pizzolitto年代,Pandolfi M, Fasola G, Piga, Puglisi F

胸苷磷酸化酶表达和受益于卡培他滨在晚期乳腺癌患者。

安杂志。2009;2月20 (2):265 - 71。doi: 10.1093 / annonc / mdn592。Epub 2008 9月2。

PubMed ID

18765464 (在PubMed

]

文摘

背景和目的:卡培他滨是一种口头可利用药物前体,通过几个酶步骤转化为5 -氟尿嘧啶,最后是由胸苷磷酸化酶(TP)。TP已经报告给上级表达癌组织与正常相比。本研究旨在评估潜在的TP的表达之间的关系和转移性乳腺癌患者受益于卡培他滨(BC)。方法:免疫组织化学TP和其他生物标记进行石蜡包埋公元前61患者的癌组织至少有三个周期的治疗卡培他滨单药为转移性疾病。所有病人收到卡培他滨1000毫克/米(2)b.i.d.天1 - 14每21天。以下变量分析作为潜在的受益于卡培他滨的决定因素:TP的表达,雌激素受体(ER)和孕激素受体状态,人类表皮生长因子受体2 (her - 2)状态,MIB-1表达式,性能状态卡培他滨治疗之初,在诊断阶段,年级,内脏转移的初卡培他滨治疗,和以前的化疗。结果:总体而言,发展(TTP)的平均时间为6.5个月(范围1.4 - -33)。多变量分析,ER状态(风险比(人力资源)发展= 0.31;95%可信区间(CI) = 0.15 - -0.64;P = 0.002),开始时存在内脏转移卡培他滨治疗(HR = 2.30; 95% CI = 1.21-4.39; P = 0.01), and capecitabine as first- or second-line treatment (HR = 2.28; 95% CI = 1.21-4.32; P = 0.01) independently predicted TTP. TP was highly expressed in 34 of 61 cases (55.7%). In the subgroup of patients with TP-expressing tumor, TTP was significantly longer in patients who received anthracyclines and taxanes before capecitabine (median TTP 7.5 versus 3.3 months, P = 0.01, log-rank test). Similarly, patients with a TP-positive tumor showed a longer TTP if they received taxanes before capecitabine than patients with TP-positive tumor who did not receive this treatment (7.3 versus 3.4 months, P = 0.03). CONCLUSIONS: These data provide further evidence that TP expression in BC could represent a biomarker of sensitivity to capecitabine treatment. Prospective studies with translational approach are desirable to confirm the predictive and prognostic role of TP.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

卡培他滨